Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology
- Date 29 Mar 2021
Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal. The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at www.nature.com/articles/s41598-021-85545-3.
As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer.
You might also be interested in these articles
Ricardo joins Scottish hydrogen association
Tue 20 Apr 2021
Ricardo UK Ltd
Will Downie named in The Medicine Maker’s Power List for 2021
Tue 20 Apr 2021
Vectura Delivery Devices Ltd
JM announces strategic partnership for sustainable battery materials production and secures critical raw materials supply
Tue 20 Apr 2021
Johnson Matthey